

Mirko Farina

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3822873/publications.pdf>

Version: 2024-02-01

40
papers

503
citations

840728

11
h-index

677123

22
g-index

42
all docs

42
docs citations

42
times ranked

762
citing authors

#	ARTICLE	IF	CITATIONS
1	Digital PCR improves the quantitation of DMR and the selection of CML candidates to TKIs discontinuation. <i>Cancer Medicine</i> , 2019, 8, 2041-2055.	2.8	63
2	Short course of bortezomib in anemic patients with relapsed cold agglutinin disease: a phase 2 prospective GIMEMA study. <i>Blood</i> , 2018, 132, 547-550.	1.4	61
3	Genomic profiling identifies somatic mutations predicting thromboembolic risk in patients with solid tumors. <i>Blood</i> , 2021, 137, 2103-2113.	1.4	57
4	The e13a2 BCR α -ABL transcript negatively affects sustained deep molecular response and the achievement of treatment-free remission in patients with chronic myeloid leukemia who receive tyrosine kinase inhibitors. <i>Cancer</i> , 2019, 125, 1674-1682.	4.1	45
5	Adult onset hemophagocytic lymphohistiocytosis prognosis is affected by underlying disease and coexisting viral infection: analysis of a single institution series of 35 patients. <i>Hematological Oncology</i> , 2017, 35, 828-834.	1.7	36
6	Prognostic role of baseline ¹⁸ F-FDG PET/CT parameters in MALT lymphoma. <i>Hematological Oncology</i> , 2019, 37, 39-46.	1.7	33
7	Feasibility of tumor-derived exosome enrichment in the oncohematology leukemic model of chronic myeloid leukemia. <i>International Journal of Molecular Medicine</i> , 2019, 44, 2133-2144.	4.0	27
8	Multidimensional geriatric assessment for elderly hematological patients (≥ 60 years) submitted to allogeneic stem cell transplantation. A French-Italian 10-year experience on 228 patients. <i>Bone Marrow Transplantation</i> , 2020, 55, 2224-2233.	2.4	23
9	Therapeutically targeting SELF-reinforcing leukemic niches in acute myeloid leukemia: A worthy endeavor?. <i>American Journal of Hematology</i> , 2016, 91, 507-517.	4.1	21
10	RT-qPCR versus Digital PCR: How Do They Impact Differently on Clinical Management of Chronic Myeloid Leukemia Patients?. <i>Case Reports in Oncology</i> , 2021, 13, 1263-1269.	0.7	18
11	Advances in CMV Management: A Single Center Real-Life Experience. <i>Frontiers in Cell and Developmental Biology</i> , 2020, 8, 534268.	3.7	16
12	Changes in Stem Cell Transplant activity and procedures during SARS-CoV2 pandemic in Italy: an Italian Bone Marrow Transplant Group (GITMO) nationwide analysis (TransCOVID-19 Survey). <i>Bone Marrow Transplantation</i> , 2021, 56, 2272-2275.	2.4	12
13	Exosomes and Extracellular Vesicles in Myeloid Neoplasia: The Multiple and Complex Roles Played by These "Magic Bullets". <i>Biology</i> , 2021, 10, 105.	2.8	11
14	Postremission therapy with repeated courses of high-dose cytarabine, idarubicin, and limited autologous stem cell support achieves a very good long-term outcome in European leukemia net favorable and intermediate-risk acute myeloid leukemia. <i>Hematological Oncology</i> , 2020, 38, 754-762.	1.7	9
15	Molecular response and quality of life in chronic myeloid leukemia patients treated with intermittent TKIs: First interim analysis of OPTIMA study. <i>Cancer Medicine</i> , 2021, 10, 1726-1737.	2.8	9
16	Comparative Mutational Profiling of Hematopoietic Progenitor Cells and Circulating Endothelial Cells (CECs) in Patients with Primary Myelofibrosis. <i>Cells</i> , 2021, 10, 2764.	4.1	8
17	Results of an Innovative Program for Surveillance, Prophylaxis, and Treatment of Infectious Complications Following Allogeneic Stem Cell Transplantation in Hematological Malignancies (BATMO Protocol). <i>Frontiers in Oncology</i> , 0, 12, .	2.8	8
18	<i>ETV6</i> : A Candidate Gene for Predisposition to "Blend Pedigrees"? A Case Report from the NEXT-Family Clinical Trial. <i>Case Reports in Hematology</i> , 2020, 2020, 1-7.	0.4	7

#	ARTICLE	IF	CITATIONS
19	The possible role of mutated endothelial cells in myeloproliferative neoplasms. <i>Haematologica</i> , 2021, 106, 2813-2823.	3.5	7
20	Is Having Clonal Cytogenetic Abnormalities the Same as Having Leukaemia?. <i>Acta Haematologica</i> , 2016, 135, 39-42.	1.4	6
21	Case Report: Late Onset of Myelodysplastic Syndrome From Donor Progenitor Cells After Allogeneic Stem Cell Transplantation. Which Lessons Can We Draw From the Reported Case?. <i>Frontiers in Oncology</i> , 2020, 10, 564521.	2.8	5
22	How We Manage Myelofibrosis Candidates for Allogeneic Stem Cell Transplantation. <i>Cells</i> , 2022, 11, 553.	4.1	5
23	Development of BCR-ABL1 Transgenic Zebrafish Model Reproducing Chronic Myeloid Leukemia (CML) Like-Disease and Providing a New Insight into CML Mechanisms. <i>Cells</i> , 2021, 10, 445.	4.1	4
24	Comparative Somatic Mutational Profiling of CD34+ Hematopoietic Precursors (HSC) and Circulating Endothelial Cells (CEC) in Patients with Primary Myelofibrosis (PMF). <i>Blood</i> , 2019, 134, 1684-1684.	1.4	3
25	Increased Interleukin-8 (IL8)-CXCR2 Signaling Promotes Progression of Bone Marrow Fibrosis in Myeloproliferative Neoplasms. <i>Blood</i> , 2020, 136, 6-7.	1.4	3
26	Identification of a Novel Mutation Predisposing to Familial AML and MDS Syndrome By a NGS Approach. <i>Blood</i> , 2018, 132, 4387-4387.	1.4	1
27	Comparative Monitoring of Minimal Residual Disease (MRD) By RT-Quantitative (RT-qPCR) and Digital PCR (dPCR) in Ph+ Chronic Myeloid Leukemia (CML) Patients Treated with TKIs for Recognition of Stable Deep Molecular Response (DMR) and Identification of Best Candidates to TKIs Treatment Discontinuation. <i>Blood</i> , 2018, 132, 3012-3012.	1.4	1
28	Extended Mutational Profiling By MSK-IMPACT™ Identifies Mutations Predicting Thromboembolic Risk in Patients with Solid Tumor Malignancy. <i>Blood</i> , 2019, 134, 633-633.	1.4	1
29	CT-027: Multidimensional Geriatric Assessment for Elderly Hematological Patients (>60 years) Submitted to Allogeneic Stem Cell Transplantation; A French-Italian 10-year Experience on 228 Patients. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2020, 20, S213-S214.	0.4	0
30	CT-290: Clinical Frailty Scale as a Novel Tool to Evaluate Patients' Eligibility for Allogeneic Stem Cell Transplant: A Single-Center Experience on 234 Patients >50 Years Old. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2021, 21, S452.	0.4	0
31	Poster: CT-290: Clinical Frailty Scale as a Novel Tool to Evaluate Patients' Eligibility for Allogeneic Stem Cell Transplant: A Single-Center Experience on 234 Patients >50 Years Old. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2021, 21, S258.	0.4	0
32	Do Unexpected and Cryptic FISH Lesions Of Chromosomally Normal MDS Patients Have Any Prognostic Relevance?. <i>Blood</i> , 2013, 122, 1549-1549.	1.4	0
33	Can Allo-HSCT Improve the Poor Clinical Outcome of the "Internal Tandem Duplication" of the FLT3 Gene?. <i>Blood</i> , 2014, 124, 5938-5938.	1.4	0
34	Alternative Splicing of hTERT Exon 7 in AML: Biological Function and Prognostic Significance. <i>Blood</i> , 2014, 124, 1019-1019.	1.4	0
35	A Gene Panel NGS-Based Strategy for Genomic Characterization of Acute Myeloid Leukemias (AMLs). <i>Blood</i> , 2015, 126, 4952-4952.	1.4	0
36	The Detection of Minimal Residual Disease By Multiparameter Flow Cytometry Predicts a Higher Risk of Relapse in Patients with ELN Intermediate Risk Acute Myeloid Leukemia Where Molecular Markers Are Not Available. <i>Blood</i> , 2016, 128, 2882-2882.	1.4	0

#	ARTICLE	IF	CITATIONS
37	Postremission Therapy with Repeated Courses of HD-Arac, Idarubicin and Limited Autologous Stem Cell Support Achieves a Very Good Long-Term Outcome in ELN Favourable and Intermediate-Risk AML Except in NPM-Mutated Patients Where Relapse May Occur Even after Five Years. <i>Blood</i> , 2016, 128, 3993-3993.	1.4	0
38	Combining Imatinib-Following-Nilotinib Treatment in First Line Therapy for Chronic Phase Chronic Myeloid Leukemia. Update from the PhilosoPhi34 Study at 24 Months of Follow-up. <i>Blood</i> , 2018, 132, 5435-5435.	1.4	0
39	First Interim Report of the Italian Multicentric Phase-III Randomized Study to Optimize TKIs Multiple Approaches - (OPTkIMA) in Elderly Patients (older than 60 years) with Ph+ Chronic Myeloid Leukemia (CML) and MR3.0/ MR4.0 Stable Molecular Response. <i>Blood</i> , 2018, 132, 4251-4251.	1.4	0
40	R-Interferon Treatment before Imatinib Reverses the Negative Impact of e13a2 Transcript Type on Treatment Free Remission Duration after Tyrosine Kinase Inhibitors Discontinuation in Chronic Myeloid Leukemia Patients. <i>Blood</i> , 2019, 134, 4146-4146.	1.4	0